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Abstract: Osteosarcoma is a highly aggressive bone cancer and the second most frequent cause of cancer-
associated death in childhood and adolescence. Pulmonary metastases account for the high mortality rate
in osteosarcoma patients. Therefore, novel therapeutic approaches, efficiently restraining the metastatic
disease, are mandatory for a significant improvement of the currently poor patients’ survival. Although
initial studies with antibodies targeting insulin-like growth factor receptor (IGF-IR) showed promising
potential for the treatment of patients with bone and soft tissue sarcomas, phase II clinical trials revealed
variable results, which implied activation of alternative signaling pathways leading to therapy resistance.
Since a cross-talk between IGF-IR and the epidermal growth factor receptor (EGFR) has been demon-
strated in several cancer types, co-targeting of these two receptors was considered in the present study
as a valuable therapeutic strategy to overcome single-agent treatment resistance in osteosarcoma. The
effects of IGF-IR and/or EGFR targeting by intraperitoneal administration of the monospecific IGF-IR
antibody R1507 or the EGFR antibody Cetuximab or the bispecific IGF-IR/EGFR antibody XGFR*
on primary tumor growth and pulmonary metastasis were investigated in an intratibial human xenograft
osteosarcoma mouse model. In vitro functional assays demonstrated that targeting IGF-IR and EGFR
didn’t affect osteosarcoma cell viability, but inhibited ligand-activated intracellular signaling and cell
migratory capacity. The blocking potential of ligand-induced signaling in vitro was similar for all anti-
bodies, but, in vivo, only XGFR* treatment significantly inhibited intratibial primary tumor growth and
pulmonary metastasis. The therapeutic response to XGFR* was associated with an infiltration of innate
immune system effector cells into the tumor microenvironment. Taken together, our study highlights the
bispecific anti-IGF-IR/EGFR antibody XGFR* as an innovative promising effective candidate for the
treatment of metastatic osteosarcoma and provides the rationale for future clinical studies.
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Abstract: Osteosarcoma is a highly aggressive bone cancer and the second most frequent cause of cancer-associat-
ed death in childhood and adolescence. Pulmonary metastases account for the high mortality rate in osteosarcoma 
patients. Therefore, novel therapeutic approaches, efficiently restraining the metastatic disease, are mandatory for 
a significant improvement of the currently poor patients’ survival. Although initial studies with antibodies targeting 
insulin-like growth factor receptor (IGF-IR) showed promising potential for the treatment of patients with bone and 
soft tissue sarcomas, phase II clinical trials revealed variable results, which implied activation of alternative sig-
naling pathways leading to therapy resistance. Since a cross-talk between IGF-IR and the epidermal growth factor 
receptor (EGFR) has been demonstrated in several cancer types, co-targeting of these two receptors was considered 
in the present study as a valuable therapeutic strategy to overcome single-agent treatment resistance in osteo-
sarcoma. The effects of IGF-IR and/or EGFR targeting by intraperitoneal administration of the monospecific IGF-IR 
antibody R1507 or the EGFR antibody Cetuximab or the bispecific IGF-IR/EGFR antibody XGFR* on primary tumor 
growth and pulmonary metastasis were investigated in an intratibial human xenograft osteosarcoma mouse model. 
In vitro functional assays demonstrated that targeting IGF-IR and EGFR didn’t affect osteosarcoma cell viability, but 
inhibited ligand-activated intracellular signaling and cell migratory capacity. The blocking potential of ligand-induced 
signaling in vitro was similar for all antibodies, but, in vivo, only XGFR* treatment significantly inhibited intratibial pri-
mary tumor growth and pulmonary metastasis. The therapeutic response to XGFR* was associated with an infiltra-
tion of innate immune system effector cells into the tumor microenvironment. Taken together, our study highlights 
the bispecific anti-IGF-IR/EGFR antibody XGFR* as an innovative promising effective candidate for the treatment of 
metastatic osteosarcoma and provides the rationale for future clinical studies.
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Introduction
Osteosarcoma is the most common primary 
malignant bone cancer in children and young 
adults [1]. With predominant metastasis to the 
lungs, osteosarcoma is a highly aggressive dis-
ease, reflected by the fact that 20% of patients 
have detectable metastases at diagnosis and 
80% of the patients initially presenting with 
localized disease subsequently develop metas-
tases [2]. Multiple efforts to improve the treat-
ment efficacy in patients with metastastic dis-
ease unfortunately failed to improve the 
survival rates, which plateaued at 20% over the 
past decades. Hence, it is of outmost impor-
tance to develop novel innovative therapeutic 
strategies that predominantly and more effec-
tively suppress metastasis, the major cause of 
death of osteosarcoma patients. 
Potential targets include the insulin-like growth 
factor-1 receptor (IGF-IR) and the epidermal 
growth factor receptor (EGFR). They are cell 
surface-located transmembrane tyrosine kinas-
es that are frequently overexpressed in a vari-
ety of human cancers [3, 4]. Upon activation, 
IGF-IR and EGFR affect tumor growth and pro-
gression by regulation of tumor cell prolifera-
tion, inhibition of apoptosis and activation of 
angiogenesis via the PI3K-Akt and RAS-RAF-
MAPK pathways.
IGF-IR has been implicated in the pathogenesis 
of sarcomas. It has been shown that human 
osteosarcoma cells are mitogenically respon-
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sive to IGF-1 in vitro. IGF-1 receptor stimulation 
also contributed to increased invasive activity 
of human and canine osteosarcoma cells [5]. 
Moreover, hypophysectomy in mice, lowering 
IGF-1 levels, reduced primary tumor growth and 
metastasis of murine osteosarcoma [6, 7]. 
Targeting various sarcoma types with different 
IGF-IR antibodies has already been performed 
[8]. Most of the preclinical studies, however, 
focused only on the effects on primary tumor 
growth in subcutaneous tumor models in mice, 
but, importantly, effects on metastatic dissemi-
nation have so far not been investigated in sar-
comas in general and in osteosarcoma in par-
ticular. [9-11]. Hence, in the present study, we 
focused on the effects of IGF-IR targeting on 
pulmonary metastasis of human osteosarcoma 
cell line-derived intratibial tumors in mice. We 
intraperitoneally treated mice with R1507 anti-
body, a fully human IgG1-type monoclonal anti-
body directed against the human IGF-IR [11]. 
Phase I and phase II clinical trials in patients 
with solid tumors showed that R1507 is well tol-
erated and shows tumor suppressive activity 
especially in Ewing’s sarcoma [12, 13]. R1507 
had limited activity in patients with bone and 
soft tissue sarcomas and considerable variabil-
ity in the outcome of patients in response to 
anti-IGF-IR therapy was observed [14]. Low 
response rates, already described in a variety 
of cancer types, were presumably due to 
acquired resistance mechanisms such as acti-
vation of alternative signaling pathways. Cor- 
responding signaling molecules may include 
MET, platelet-derived growth factor (PDGFR) or 
EGFR [15-17]. 
The biological relevance of EGFR for osteosar-
coma pathogenesis is controversially discussed 
[18, 19]. Interestingly, targeting human EGFR 
with Cetuximab, a chimeric mouse/human 
monoclonal antibody of the IgG1 subclass, 
together with natural killer cells has been 
employed to kill human osteosarcoma EGFR-
expressing cells even at low receptor density 
[20]. A phase II clinical trial of Cetuximab in 
patients with metastatic or locally advanced 
soft tissue or bone sarcoma reported that this 
antibody has a good safety profile but is not 
effective as a single agent in advanced sarco-
ma [21]. It is, however, important to note that 
this study was not conclusive since only two 
osteosarcoma patients with tumor tissue lack-
ing EGFR expression were included. Therefore, 
further studies with Cetuximab in osteosarco-
ma patients are needed. Interestingly, Cetuxi- 
mab has so far not been investigated in osteo-
sarcoma animal models.
A cross-talk between IGF-IR and EGFR has been 
demonstrated in several cancer types [22, 23]. 
In addition, EGFR has been shown to be 
involved in the regulation of the secretion of 
CCN1 [24], a protein that was recently found to 
have metastasis promoting activity in osteosar-
coma [25]. Thus, combined targeting of IGF-IR 
and EGFR in osteosarcoma needs to be investi-
gated. Bispecific antibodies that simultaneous-
ly target two different antigens are nowadays 
considered as a next generation of effective 
molecules for cancer therapy [26]. In addition 
to simultaneous targeting of two different cell 
surface receptors on tumor cells and thereby 
blocking two different signaling pathways, 
bispecific antibodies have also the valuable 
therapeutic property to redirect specific 
immune effector cells to tumor cells, which 
leads to enhanced tumor cell killing [27].
In order to simultaneously block both IGF-IR 
and EGFR, we made use of a novel bispecific 
antibody XGFR*, that was found to have a 
potent tumor suppressive activity in an ortho-
topic xenograft mouse model of pancreatic 
cancer [28]. This antibody is an affinity-matured 
antibody targeting IGF-IR and EGFR based on 
the glycoengineered bispecific IgG antibody 
XGFR, previously described to have in vitro and 
in vivo anti-tumor activity in several xenograft 
mouse tumor models including pancreatic, lung 
and colorectal cancer models [29]. XGFR*, a 
highly functionally improved molecule with 
maximal monovalent binding of IGF-IR and 
EGFR, bears afucosylated Fc-portion optimal 
to provoke antibody-dependent cell-mediated 
cytotoxicity (ADCC). 
The main aim of the here presented study was 
to investigate and compare in an intratibial 
human xenograft osteosarcoma mouse model 
the primary tumor and metastasis suppressive 
efficacy of monospecific IGF-IR- or EGFR-
blocking antibodies administered alone or in 
combination and of a bispecific IGF-R/EGFR 
antibody. 
Materials and methods
Cell culture and antibodies
The human osteosarcoma cell lines SaOS-2 
(HTB-85), HOS (CRL-1543) and 143-B (CRL-
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8303) cells were obtained from American Type 
Culture Collection (ATCC) (Rockville, MD). LM5 
cells were kindly provided by E.S. Kleinerman 
(M.D. Anderson Cancer Center, Houston, TX), 
HUO9 and HUO9-M132 (M132) cells by M. Tani 
(National Cancer Center Hospital, Tokyo, 
Japan), MG63 cells by G. Sarkar (Mayo Clinic, 
Rochester, MN) and MG63-M8 (M8) cells by 
W.T. Zhu (Tongji Hospital, Huazhong University 
of Science and Technology, Wuhan, China). 
143-B and SaOS-2 cells were stably trans-
duced with a LacZ gene revealing SaOS-2/LacZ 
and 143-B/LacZ cells. They were selected as 
previously reported [30-32] and cultured in tis-
sue culture medium containing DMEM (4.5 g/l 
glucose)/HamF12 (1:1) medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% heat 
inactivated fetal bovine serum (FBS; Lubio 
Science, Lucerne; Switzerland), referred to as 
complete medium in the text. The cells were 
kept at 37°C in a humidified atmosphere of 5% 
CO
2
 and 95% air. The cell line authentication 
was done by short tandem repeat DNA profiling 
(Microsynth; Balgach, Switzerland) with a 
PowerPlex®16HS system (Promega. Madison, 
WI) and by comparison with the German 
Collection of Microorganisms and Cell Cultures 
Database (DSMZ). SaOS-2/LacZ and 143-B/
LacZ cells were used in in vitro functional 
assays. In order to enable visualization of tumor 
cells within mouse tissues in vivo and ex vivo, 
143-B/LacZ cells were additionally transduced 
with an mCherry gene (143-B/mCherry/LacZ 
cells) as described recently [33]. Roche Dia- 
gnostics GmbH (pRED Discovery Oncology, 
RICM, Germany) kindly provided R1507 (a fully 
humanized IgG1 monoclonal antibody directed 
against the extracellular portion of IGF-1R at a 
stock concentration of 25.6 mg/ml), XGFR* 
(RO6842831, a bispecific anti-IGF-1R/EGFR 
antibody at a stock concentration of 5.9 mg/
ml) and Cetuximab (Erbitux; Merck KGaA, 
Darmstadt, Germany), a chimeric IgG1 type 
monoclonal anti-EGFR antibody at a stock con-
centration of 5 mg/ml.
RNa extraction, cDNa synthesis and quan-
titative real-time polymerase chain reaction 
(qPCR)
Total RNA was isolated with an RNeasy Mini Kit 
(Qiagen, Hilden, Germany; 74104) as described 
in the protocol provided by the manufacturer. 
RNA concentrations and purity were analyzed 
by OD 260/280 measurements in a NanoDrop 
device (Thermo Scientific, Waltham, MA). 1 µg 
of total RNA was transcribed to cDNA with a 
High-Capacity cDNA Reverse Transcription Kit 
with Rnase Inhibitor (Applied Biosystems, 
Foster City, CA; 4374966) following the manu-
facturer’s instructions. Real-time qPCR was 
conducted on cDNA equivalent to 10 ng of 
starting RNA using a Power SYBR Green PCR 
Master Mix (Applied Biosystems, 4367659) 
with a StepOne-Plus Real-Time PCR System 
(Applied Biosystems). Primers used are listed in 
Table 1. The results obtained from three inde-
pendent RNA preparations of individual cell 
lines were analyzed with StepOne Software ver-
sion 2.1 (Applied Biosystems). Relative expres-
sion levels of individual transcripts were calcu-
lated by the comparative (ΔΔCT) method and 
normalized to GAPDH. 
Stimulation and downregulation experiments 
and Western blotting 
In stimulation experiments, cells were cultured 
for 36 hours in medium depleted of FBS. After 
starvation the cells were left untreated or pre-
incubated for 1 hour with control IgG (Jackson 
Immunoresearch Labs Inc, West Grove, PA; 
009-000-003; 20 µg/ml) or with R1507 (2 or 
20 µg/ml) or Cetuximab (2 or 20 µg/ml) or with 
a combination of R1507 and Cetuximab (20 
µg/ml) or with XGFR* (2 or 20 µg/ml) prior to 
stimulation with IGF-1 (10 ng/ml) or EGF (10 
ng/ml) or the combination of both growth 
factors.
In order to investigate effects of IGF-IR- and 
EGFR-targeting antibodies on IGF-IR and EGFR 
protein expression, the cells were incubated in 
complete tissue culture medium alone for 24 
hours or in medium containing 1 µg/ml of 
Table 1. Primer pairs used in qRT-PCR
Gene Name 
(human)
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R1507 or Cetuximab or XFGR* for 1, 2, 6 or 24 
hours. 
The preparation of protein cell extracts and 
Western blot analysis were conducted as pre- 
viously described [32]. Antibodies used were 
anti-IGF-IR (3027, dilution 1:1000), anti-EGFR 
(4267, dilution 1:1000), anti-phospho-Erk (9101, 
dilution 1:1000), anti-total-Erk (9102, dilution 
1:1000), anti-phospho-Akt (4060, dilution 
1:1000), anti-total-Akt (9272, dilution 1:1000) 
purchased from Cell Signaling Technology 
(Beverley, MA), anti-GAPDH (FL-335, dilution 
1:3000) and HRP-conjugated secondary anti-
bodies (sc2054, dilution 1:5000) were obtain- 
ed from Santa Cruz Biotechnologies (Dallas, 
TX) and antibodies to β-actin (dilution 1:10000) 
from Merck Millipore (Darmstadt, Germany).
Immunocytochemistry
Confluent 143-B cells seeded on round cover 
slips were fixed with 2% formalin for 10 minutes 
at room temperature (RT), quenched with com-
plete cell culture medium for 1 hour at RT fol-
lowed by incubation with IgG control, R1507, 
Cetuximab or XGFR* (2 µg/ml) for 2 hour at 
RT in PBS, 0.1% BSA. After three washes, the 
cells were incubated with Alexa546 anti-human 
IgG (Invitrogen; 1:400) for 30 minutes at RT 
and after three washes slides were mounted 
with ImmuMount (Thermo Shandon; Pittsburgh, 
PA). Cells were viewed with a Zeiss Axiovert.Z1 
fluorescence microscope equipped with a 
DsRed fluorescence filter set, a 10 × objective 
and an AxioCam MRm camera (Carl Zeiss AG, 
Feldbach, Switzerland).
Cell viability assay
3 × 103 SaOS-2 or 0.5-1 × 103 143-B cells per 
well were seeded in tissue culture medium in 
96-well plates and allowed to adhere overnight. 
The cells were then incubated in triplicates with 
increasing concentrations of R1507, Cetuximab 
or XGFR* antibodies for 72 hours. Following 
antibody treatment, the cells were incubated 
with 10 µl/well of WST-1 reagent (Roche, 
Rotkreuz, Switzerland) for 3 hours and the cell 
viability was then assessed as previously de- 
scribed [34]. Three independent experiments 
were performed.
Transwell migration assay
The migratory properties of osteosarcoma cells 
were assessed in a transwell migration assay 
as reported previously [32]. Briefly, 104 143-B 
or 2 × 104 SaOS-2 cells were seeded in the 
absence or presence of R1507 (1 µg/ml) or 
Cetuximab (1 µg/ml) or the combination of 
R1507 and Cetuximab (1 µg/ml) or of XGFR (1 
µg/ml) antibodies diluted in serum-free medi-
um and allowed to migrate for 6 hours or 24 
hours towards FBS-containing medium, respec-
tively. The number of migrated cells in the ana-
lyzed area was determined with ImageJ soft-
ware (http://rsb.info.nih.gov/ij/) and the total 
number of migrated cells per well was then cal-
culated. The number of migrated cells treated 
with targeting antibodies was normalized to the 
number of migrated untreated cells set to 
100%. The experiments were done in dupli-
cates and repeated three times.
In vivo treatment study
The Ethics Committee of the Canton Zurich 
Veterinary Office approved the animal study 
that was subsequently conducted in accor-
dance with the Swiss Animal Protection Law. 
Eight to ten weeks old female SCID/CB17 
immunocompromised mice, purchased from 
Charles River Laboratories, were intratibially 
injected with 105 143-B/mCherry/LacZ cells in 
10 µl of PBS/0.05% EDTA on day 0. Primary 
tumor development was examined weekly by 
X-ray and caliper measurements as previously 
described [35]. Ten days after tumor cell injec-
tion (TCI), when the primary tumor became 
detectable by X-Ray in all animals, the mice 
were randomly distributed according to their 
weight into 5 groups and the intraperitoneal 
weekly treatment with antibodies was initiated. 
The control group received the vehicle (physio-
logical saline, n=12), whereas the treatment 
groups were injected with R1507 (10 mg/kg of 
body weight, n=10), or Cetuximab (10 mg/kg, 
n=12), or a combination of R1507 and 
Cetuximab (10 mg/kg + 10 mg/kg, n=12) or 
with XGFR* (20 mg/kg, n=10). The XGFR* anti-
body concentration of 20 mg/kg was used in 
order to ensure equimolar concentrations of 
dosing between XGFR* and the combination of 
R1507 and Cetuximab. The animals were sacri-
ficed 27 days after TCI and the primary tumors 
and in situ perfused lungs were dissected, 
X-Gal stained and the numbers of metastases 
on the lung surface were quantified as reported 
[31, 35].
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Immunohistochemistry
Pieces of dissected primary tumors were imme-
diately embedded in Tissue-Tek® O.C.T. Com- 
pound (Sakura Finetek, Torrance, CA), frozen on 
dry ice and kept at -80°C prior to cutting. The 
presence of natural killer (NK) cells was investi-
gated by immunohistochemistry on frozen tis-
sue sections according to standard protocols 
using a pan-NK anti-mouse CD49b antibody 
(BD Pharmingen, Allschwil, Switzerland; dilution 
1:40). Slides incubated with secondary anti-
body alone served as negative controls. Cell 
nuclei were counterstained with hematoxylin. 
Primary tumor sections from three mice per 
group were analyzed. At least 3 images of ran-
domly selected areas per tumor section were 
taken with an AxioCam MRc camera connected 
to the Zeiss Observer.Z1 inverted microscope 
(Carl Zeiss AG, Feldbach, Switzerland) set at 10 
× magnification. Positive NK staining (red) and 
negative (purple) staining were separated using 
Fiji software [36]. The area percentage of the 
stain was defined as positive stained area 
(number of red pixels) over total tissue area 
studies investigating in an intratibial osteosar-
coma mouse model primary tumor and metas-
tasis suppressive effects of IGF-IR- and EGFR-
targeting antibodies including the bispecific 
XFGR*, we first studied the expression of IGF-IR 
and EGFR in a panel of eight human osteosar-
coma cell lines. Western blot analysis of whole 
cell extracts revealed wide expression of IGF-IR 
in all osteosarcoma cell lines investigated 
(Figure 1A, upper panel). EGFR, on the other 
hand, was only expressed in six out eight cell 
lines (Figure 1A, lower panel). Interestingly, the 
highest expression of IGF-IR was observed in 
cell lines in which the expression of EGFR was 
non-detectable or low (HUO9, M132, SaOS-2, 
LM5). In order to identify the cell lines with pos-
sible autocrine IGF-IR and EGFR signaling axes, 
we investigated the expression of respective 
ligands at the mRNA level by qPCR. The levels 
of IGF-1 mRNA were very low or undetectable in 
all cell lines analyzed (40 cycles; data not 
shown). The level of expression of mRNA encod-
ing TGFα, a ligand of EGFR, was found highest 
in the M132 cell line (Figure 1B). Overall the 
levels of EGF mRNA expression in the cell lines 
Figure 1. Expression of IGF-IR and EGFR and of EGFR ligands in human os-
teosarcoma cell lines. (A) IGF-IR and EGFR protein levels in whole cell ex-
tracts were examined by Western blot analysis using antibodies to IGF-IR 
or EGFR and to GAPDH or Actin as protein loading controls. Representative 
Western blots of three independent experiments. The levels of mRNA encod-
ing TGFα (B) and EGF (C) were analyzed by quantitative RT-PCR and normal-
ized to those of GAPDH in total RNA extracts. The relative expression levels 
were plotted as % of the maximal value. Results are presented as the mean 
± SEM of at least 3 independent experiments.
(number of red and purple 
pixels). 
Statistical analysis
Statistical significance of dif-
ferences between the experi-
mental groups was deter-
mined using a one or two-way 
ANOVA test with Dunnett’s 
Multiple Comparison or New- 
man-Keuls Multiple Compari- 
son post-tests and P<0.05 
was considered significant. All 
analyses were done with 
GraphPad Prism Version 5.01 
(GraphPad Software, Inc., La 
Jolla, CA). The results are pre-
sented as means ± standard 
error of the mean (SEM). 
Results
Expression analysis of IGF-IR 
and EGFR and corresponding 
ligands in established human 
osteosarcoma cell lines 
With the purpose to select the 
appropriate cell lines for the 
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investigated were low, as indicated by Ct values 
for EGF transcripts that varied between 30 and 
35 cycles. Among the eight cell lines the SaOS-
2 and LM5 cell lines had the highest EGF tran-
script levels (Figure 1C). 
In summary, IGF-IR and EGFR were found to be 
expressed in all or in the vast majority, respec-
tively, of the here investigated human osteosar-
coma cell lines. Non-detectable expression of 
IGF-1 encoding mRNA and the overall low 
expression of TGFα and EGF mRNA transcripts 
in most of the investigated cell lines implicate 
that autocrine signaling loops are largely inexis-
tent in the majority of the osteosarcoma cell 
lines analyzed in the present study.
Effects of antibody-based targeting of IGF-IR 
and EGFR on their downstream signaling in 
vitro
One of the mechanisms of antibody-based ther-
apy of cancer involves antibody-mediated blo- 
cking of ligand/receptor interaction on tumor 
cells and, as a consequence, inhibition or com-
plete abrogation of the receptor signaling [37]. 
Therefore, we next evaluated the ability of 
Ki-Ras transformation [38] and, therefore, 
exhibit constitutive Erk signaling, we did not 
investigate Erk phosphorylation upon IGF-IR 
and EGFR blocking. In serum-starved SaOS-2 
cells, however, pre-incubation with R1507 pro-
voked a prominent inhibition of IGF-1-stimulat- 
ed Erk phosphorylation, but minimally affected 
Akt phosphorylation (Figure 2C). Conversely, 
Cetuximab did not affect EGF-stimulated Erk 
signaling, but, when used at a high concentra-
tion, inhibited Akt phosphorylation (Figure 2C). 
The combination of R1507 and Cetuximab had 
minimal effects on IGF-1- and EGF-stimulated 
signaling in SaOS-2 cells (Figure 2D). In con-
trast, as shown in Figure 2D, pre-incubation of 
SaOS-2 cells with XGFR* led to lower levels of 
both phosphorylated Erk and Akt compared to 
control upon stimulation with IGF-1 and EGF. 
Importantly, incubation of the cells with the 
individual antibodies and IgG alone (in the 
absence of ligands) did not stimulate any sig-
naling in the two cell lines investigated. 
Moreover and as expected, in the absence and 
presence of IgG (control), IGF-1 or EGF-provoked 
signaling was indistinguishable in both cell 
lines.
Figure 2. Effects of R1507/Cetuximab/XGFR* on IGF-1/EGF-induced signal-
ing in 143-B and SaOS-2 cells. Serum-starved (36 hours) 143-B (A, B) or SaOS-
2 (C, D) cells were left untreated or were pre-incubated for 1 hour with control 
IgG (20 µg/ml) or with indicated concentrations of R1507 or Cetuximab (A, 
C) or a combination of R1507 and Cetuximab or with XGFR* (B, D) prior to 
stimulation with IGF-1 (10 ng/ml) or EGF (10 ng/ml) or the combination of both 
growth factors. Cell lysates were analyzed by Western blots, using indicated 
antibodies. Representative Western blots of three independent experiments.
R1507, of Cetuximab, of the 
combination of R1507 and 
Cetuximab or of XGFR* to 
inhibit ligand-activated IGF-IR 
and EGFR-mediated signal-
ing. The 143-B and SaOS-2 
cell lines were chosen for the 
here described in vitro ex- 
periments because they co-
express IGF-IR and EGFR. 
Pre-incubation of serum-sta- 
rved 143-B cells with R1507, 
Cetuximab or XGFR* inhibited 
in a dose-dependent manner 
IGF-1- and EGF-stimulated si- 
gnaling, indicated by remark-
able inhibition of the phos-
phorylation of Akt, one of the 
major effector components in 
the IGF-IR and EGFR signaling 
cascades (Figure 2A, 2B). 
R1507 and Cetuximab toge- 
ther inhibited Akt phosphory-
lation accordingly and to a 
similar extent as the bispecif-
ic antibody XGFR* (Figure 
2B). Given the fact that 143-B 
cells were generated through 
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Figure 3. Effects of R1507/Cetuximab/
XGFR* antibodies on cell viability and 
migratory properties of indicated osteo-
sarcoma cell lines. The cell viability of 
143-B (A) or SaOS-2 (B) cells upon 72 
hours treatment with indicated antibod-
ies was determined with a WST-1 assay. 
(C, D) Transwell migration assay in the 
absence or presence indicated anti-
bodies (1 µg/ml). Values represent the 
mean ± SEM; *, P<0.05, ***, P<0.001. 
UT, untreated control.
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Taken together, in 143-B cells all mono- and 
bispecific antibodies to IGF-IR and EGFR inhib-
ited ligand stimulated signaling of respective 
receptors with a remarkable potency. In SaOS-
2 cells, on the other hand, only R1507 and 
XGFR* were able to inhibit ligand-stimulated 
signaling and to a considerably lower extent 
than that observed in 143-B cells.
Effects of R1507, Cetuximab and XGFR* on in 
vitro viability and migration of osteosarcoma 
cells
In order to investigate the potential effects of 
IGF-IR and EGFR-targeting antibodies on cell 
viability we performed a WST-1 assay. The treat-
ment of 143-B cells and of SaOS-2 cells with 
increasing concentrations of R1507, Cetuximab 
or XGFR* for 72 hours had no effect on their 
viability as shown in Figure 3A and 3B, 
respectively. 
We next explored if the antibodies affect tumor 
cell migration using a transwell migration assay. 
The migration rate of 143-B cells was signifi-
cantly reduced compared to control in the pres-
ence of all antibodies as shown in Figure 3C 
(P<0.001). R1507, Cetuximab, a mixture of 
R1507 and Cetuximab or XGFR* decreased the 
migration rate to 56.2 ± 5%, 51.3 ± 3%, 34.2 ± 
3.3% and 48.7 ± 7.1% when compared to that 
of untreated control, respectively. Treatment of 
Figure 4. Effects of the antibodies R1507/
Cetuximab/XGFR* on IGF-IR/EGFR protein 
expression in 143-B cells. (A) Cell surface 
immunostaining of IGF-IR and EGFR with in-
dicated antibodies (2 µg/ml) in non-permea-
bilized cells. Bar, 100 µm. Expression levels 
of IGF-IR and EGFR in whole cell protein ex-
tracts were analyzed on Western blots using 
the indicated antibodies upon incubation 
with cell culture medium alone (untreated 
(UT) control) or with R1507 (B), Cetuximab 
(C) or XGFR* (D) at a concentration of 1 µg/
ml for the specified period of time (h, hours).
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SaoS-2 cells with R1507, combination of R1507 
and Cetuximab or with XGFR* revealed a less 
prominent effect on migration rates than in 
143-B cells. Overall the migration rates were 
reduced to approximately 65% of that observed 
in untreated cells (Figure 3D, P<0.05). SaOS-2 
cells treated with Cetuximab also showed a ten-
dency to reduced migration (Figure 3D, P>0.05). 
Collectively, these results demonstrate that tar-
geting IGF-IR and EGFR had no impact on in 
vitro cell viability, but led to the reduction of the 
migratory potential of osteosarcoma cells. 
Binding of R1507, Cetuximab and XGFR* to 
143-B cells and their effect on IGF-IR or EGFR 
protein levels
Since, in the so far described in vitro experi-
ments, the responses of 143-B cells to mono- 
and bispecific IGF-IR and EGFR blocking anti-
bodies were more robust than those observed 
in SaOS-2 cells, we decided to use a 143-B 
xenograft model for our in vivo preclinical study 
and therefore further characterized in vitro the 
interaction and resulting effects of the antibod-
ies in 143-B cells. Immunocytochemistry con-
firmed binding of the antibodies to the cell sur-
face (Figure 4A). Interestingly, binding of XGFR* 
to cell surface IGF-IR and EGFR receptors 
appeared considerably more efficient than that 
of the monospecific antibodies.
Previous studies have shown that cell surface 
targeting of IGF-IR and EGFR by antibodies can 
lead to a decrease of receptor protein expres-
sion levels through receptor internalization and 
subsequent degradation. Therefore, we investi-
gated IGF-IR and EGFR protein levels by We- 
stern blotting upon incubation of 143-B cells 
with R1507, Cetuximab or XGFR* in a time 
course experiment. R1507 provoked downreg-
ulation of IGF-IR in 143-B cells after 24 hours 
of incubation (Figure 4B). In contrast, protein 
levels of EGFR or IGF-IR remained unchanged 
upon Cetuximab- or XGFR* treatment (Figure 
4C and 4D).
In summary, the bispecific XGFR* antibody 
exhibited the most potent binding to 143-B 
cells. In contrast to Cetuximab and XGFR*, 
which did not affect protein levels of respective 
receptors, R1507 reduced IGF-IR protein 
expression levels.
XGFR* inhibits intratibial primary tumor 
growth and suppresses pulmonary metastasis 
in a xenograft osteosarcoma mouse model
The intratibial 143-B xenograft osteosarcoma 
mouse model that closely recapitulates human 
metastatic disease was used to evaluate and 
compare in vivo the response to IGF-IR and 
EGFR targeting therapy with respective mono-
specific or bispecific antibodies. Treatment of 
the mice by weekly intraperitoneal injections of 
the antibodies or vehicle (saline) was initiated 
on day 10 after intratibial tumor-cell injections 
(TCI) (Figure 5A). Three injections per mouse 
were given in total. Tumor-bearing mice in 
respective experimental groups received 10 
mg per kg of body weight of R1507 or 10 mg/
kg Cetuximab alone or 10 mg/kg of R1507 
together with 10 mg/kg Cetuximab or 20 mg/
kg XGFR* alone. XGFR* was applied at 20 mg/
kg to ensure equimolar dosing between XGFR* 
and R1507/Cetuximab combination. Develo- 
pment over time of primary tumors associated 
with osteolytic lesions in the mice tibias was 
monitored by X-Ray imaging. The X-Ray images 
of injected legs of vehicle- or XGFR*-treated 
mice are presented in Figure 5B. Primary tumor 
growth, assessed by caliper measurements, 
was significantly inhibited by Cetuximab and 
XGFR* treatment, as demonstrated by a 20% 
and 40% decrease in the final primary tumor 
volume when compared to that of the vehicle-
treated group, respectively (Figure 5C; P<0.05, 
P<0.001). Interestingly, R1507 alone or in com-
bination with Cetuximab, did not have any 
effect on primary tumor growth. 
In addition to the tumour suppressive effect, 
XGFR* had a significant anti-metastatic activi-
ty, demonstrated by quantification of ex vivo 
X-Gal stained metastases on lung surfaces 
(Figure 6A and 6B). Animals treated with XGFR* 
displayed 2.2 fold lower mean numbers of pul-
monary metastases than the vehicle-treated 
animals (Figure 6B, P<0.05). R1507, Cetuximab 
or R1507/Cetuximab combination, on the other 
hand, did not significantly alter the number of 
pulmonary metastases, although we observed 
a tendency towards a decreased number of 
metastases in Cetuximab and R1507/Cetu- 
ximab treated groups.
In summary, therapy with bispecific XGFR* had 
a more pronounced inhibitory effect on tumor 
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growth and pulmonary metastasis than the 
treatment with the monospecific IGF-IR or EGFR 
antibodies or a combination thereof.
XGFR* treatment is associated with increased 
natural killer cell infiltration into primary tumor 
tissue
Our in vivo therapy study revealed that the com-
bination of targeting both IGF-IR and EGFR with 
a single bispecific antibody has evidently supe-
rior anti-tumor and anti-metastatic efficacy 
than the dosing of individual monospecific anti-
bodies, although the blocking capacity of 
ligand-activated signaling in vitro was similar 
for all antibodies. We, therefore, hypothesized 
that antibody-dependent immune effector 
functions may contribute to XGFR* in vivo 
effectiveness. Hence, we investigated the pres-
ence of tumor-infiltrating natural killer (NK) 
cells by immunohistochemistry on primary 
tumor tissue sections using a pan-NK anti-
mouse CD49b antibody (Figure 7A). We found a 
significantly increased accumulation of NK 
cells in primary tumors of XGFR*-treated mice 
than in all the other treatment groups (Figure 
7B, P<0.05).
ing results [12-14]. Activation of alternative 
signaling pathways mediating resistance to 
single agent therapy might underlie the report-
ed variable response rates. Along these lines it 
has been demonstrated in other cancer types 
that signaling through EGFR may overcome 
resistance to IGF-IR inhibitors and vice versa 
[40, 41], implying that co-targeting these two 
receptor tyrosine kinases might provide more 
clinical benefit to osteosarcoma patients.
In the present study we investigated in vitro 
and in vivo effects of IGF-IR and/or EGFR tar-
geting by the antibodies R1507, Cetuximab and 
XGFR* in osteosarcoma. First, we were able to 
confirm the previously reported findings that 
osteosarcoma cells express functional IGF-IR 
and EGFR receptors [20, 42-45]. Ligand-
induced downstream signaling was efficiently 
suppressed by monospecific antibodies and by 
XGFR*, most prominently in 143-B cells, as 
demonstrated by reduced Akt phosphorylation. 
These results are in line with the findings in 
lung and colon carcinoma as well as in Ewing 
sarcoma cell lines [28, 29]. Despite the effec-
tive inhibition of receptor activation and R1507-
provoked IGF-IR downregulation, in vitro cell 
Figure 5. Effects of IGF-IR and EGFR targeting antibodies on primary tumor 
growth in the 143-B xenograft osteosarcoma mouse model. A. X-Ray image 
of the intratibial injection of 143-B cells into a SCID mouse taken at the 
time of the tumor cell injection (TCI) on Day 0 (left panel). Study design and 
treatment schedule of tumor bearing mice included weekly intraperitoneal 
injections of vehicle (control), R1507 (10 mg/kg body weight), Cetuximab (10 
mg/kg), R1507 and Cetuximab (10 mg/kg + 10 mg/kg) or XGFR* (20 mg/
kg) (right panel). B. Primary tumor development over time monitored by X-Ray 
imaging of tumor bearing legs at indicated time points in mice treated with 
vehicle or XGFR* antibody. C. Intratibial tumor growth over time examined 
by caliper measurements. Values are the mean ± SEM of the data collect-
ed from 12 vehicle-, Cetuximab-, R1507 + Cetuximab- and 10 R1507- and 
XGFR* treated mice; *, P<0.05; ***, P<0.001. 
Taken together, the data pre-
sented here indicate an asso-
ciation between XGFR* treat-
ment and infiltration of the 
innate immune system effec-
tor cells into the tumor 
microenvironment.
Discussion
Due to its high propensity for 
metastatic spread, osteosar-
coma is the second leading 
cause of cancer-linked death 
in childhood and adolescence 
[39]. Therefore, novel thera-
peutics, efficiently preventing 
metastatic disease, are man-
datory in order to improve the 
currently poor patients’ survi- 
val. 
Although initial studies us- 
ing IGF-IR-targeting antibod-
ies showed promising poten-
tial for the treatment of pa- 
tients with bone and soft tis-
sue sarcomas, phase II clini-
cal trials revealed discourag-
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viability was not affected, much like in a num-
ber of various cancer cell lines [46, 47]. 
static activity. Because all antibodies decreased 
motility of osteosarcoma cells in vitro, but only 
Figure 6. Effects of IGF-IR and EGFR targeting antibodies on lung metastasis 
in the 143-B xenograft osteosarcoma mouse model. A. Representative pho-
tos of lungs with X-Gal stained metastases (arrows) in indicated treatment 
groups. Bar, 250 µm. B. Quantification of pulmonary metastases on the lung 
surface of mice receiving vehicle (n=12), R1507 (n=10), Cetuximab (n=12), 
combination R1507 + Cetuximab (n=12) or XGFR* (n=10). The lungs were 
harvested and subjected to X-Gal staining 27 days after tumor cell injection. 
Values are the mean ± SEM; *, P<0.05.
Figure 7. Infiltration of natural killer cells into 143-B xenografts. A. Detection 
of natural killer (NK) cells by immunohistochemistry (CD49b; red staining). 
Representative images of primary tumor sections obtained from vehicle- or 
XGFR*-treated mice. Cell nuclei counterstained with hematoxylin (purple 
staining). Bar, 200 µm. B. Quantification of NK immunostaining in primary 
tumor sections of mice receiving vehicle (n=3), R1507 (n=3), Cetuximab 
(n=3), combination R1507 + Cetuximab (n=3) or XGFR* (n=3) treatment. 
Values are the mean ± SEM; *, P<0.05.
However, our in vivo preclini-
cal study revealed diverse 
responses to the mono- and 
bispecific antibodies. R1507 
was ineffective in inhibiting 
growth and tumor cell dis-
semination, which is consis-
tent with the restricted effica-
cy of this antibody seen in the 
clinical trials [14]. Different 
from these observations are 
the findings of a study in 
which R1507 was shown to 
delay tumor growth in four out 
of six osteosarcoma cell line 
xenograft models [11]. It is 
however noteworthy that the 
above mentioned animal stu- 
dies employed subcutaneous 
osteosarcoma mouse mod-
els, as opposed to our in vivo 
study in which we made use 
of an intratibial osteosarco-
ma mouse model, supporting 
the idea that our orthotopic 
model might have more trans-
lational relevance. In contrast 
to R1507, Cetuximab dis-
played a modest anti-tumor 
effect in vivo concordant to 
the previous report investig- 
ating effects of Gefitinib, a 
selective EGFR tyrosine kin- 
ase inhibitor, and concluding 
that EGFR is not a major driv-
er of osteosarcoma cell gro- 
wth in vitro [43]. Interestingly, 
the combination of R1507 
and Cetuximab did not affect 
tumor growth; therefore, we 
speculate that there might be 
the possibility of decreased 
binding of Cetuximab to tumor 
cells in vivo in the presence of 
R1507. Simultaneous IGF-IR 
and EGFR targeting with 
XGFR*, on the other hand, 
prominently inhibited primary 
tumor growth. Moreover, our 
preclinical study demonstrat-
ed for the first time that 
XGFR* exhibits an anti-meta-
Anti-IGF-IR/EGFR targeted therapy of human metastatic osteosarcoma in mice
1446 Am J Cancer Res 2017;7(7):1435-1449
XGFR* significantly reduced the number of lung 
metastases, we believe that the in vivo meta-
static inhibition caused by XGFR* is not a con-
sequence of a direct effect of XGFR* on tumor 
cell capacity to migrate. We provide evidence 
that XGFR* most potently binds to 143-B cells 
in vitro compared to the monospecific antibod-
ies. Furthermore, XGFR* does not induce re- 
ceptor internalization and degradation of the 
respective receptors in osteosarcoma cells. 
The prolonged display of XGFR* on cell surface 
may lead to increased ADCC as seen in other 
cancer cell models [28]. Along these lines, we 
showed that NK cells accumulate in the intratu-
moral microenvironment of XGFR*-treated ani-
mals. We, therefore, postulate that the thera-
peutic response to XGFR*, reflected in the 
inhibition of primary tumors and metastatic 
spread, is associated with the recruitment of 
immune effector cells and subsequent immune 
system-mediated cell killing. 
Our data once again underline the remarkable 
advantage of bispecific antibodies that, in addi-
tion to interfering with two different targets, 
serve as tumor-targeted immune cell recrui- 
ters [26]. The bispecific antibodies have a great 
potential in the oncology field and their combi-
nation with other treatment modalities includ-
ing chemotherapy should be explored. 
In conclusion, our study highlights the bispecif-
ic anti-IGF-IR/EGFR antibody XGFR* as a novel 
effective therapeutic option against metastatic 
osteosarcoma and provides the rationale for 
future investigations in clinical settings.
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